Analyst Jefferies today reiterated a Buy rating on Synta Pharmaceuticals Corp. (Nasdaq: SNTA). They continue to see upside to shares ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE